Mylan defeats Sanofi’s claims it illegally prevented competition to EpiPen

Sanofi-Aventis failed to demonstrate that Mylan monopolised the market for epinephrine auto-injectors used to treat severe allergic reactions, a Kansas federal court ruled in a recently unsealed opinion.


Get unlimited access to all Global Competition Review content